Mono Pharmacare (NSE:MONOPHARMA) Asset Turnover: 0.58 (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:MONOPHARMA Mono Pharmacare Ltd NSE:MONOPHARMA
9 GF Score
Price ₹10.60
! 6 Warning Signs
View Full Analysis

What is Mono Pharmacare Asset Turnover?

Mono Pharmacare NSE:MONOPHARMA -3.64% 9 Asset Turnover is 0.58 as of Sep. 2025. GuruFocus rates NSE:MONOPHARMA with a GF Score™ of 9/100. The stock has 6 warning signs investors should review.

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Mono Pharmacare's Revenue for the six months ended in Sep. 2025 was ₹663 Mil. Mono Pharmacare's Total Assets for the quarter that ended in Sep. 2025 was ₹1,147 Mil. Therefore, Mono Pharmacare's Asset Turnover for the quarter that ended in Sep. 2025 was 0.58.

Asset Turnover is linked to ROE % through Du Pont Formula. Mono Pharmacare's annualized ROE % for the quarter that ended in Sep. 2025 was 0.13%. It is also linked to ROA % through Du Pont Formula. Mono Pharmacare's annualized ROA % for the quarter that ended in Sep. 2025 was 0.04%.


Mono Pharmacare  (NSE:MONOPHARMA) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Mono Pharmacare's annulized ROE % for the quarter that ended in Sep. 2025 is

ROE %**(Q: Sep. 2025 )
=Net Income/Total Stockholders Equity
=0.41/312.095
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(0.41 / 1325.824)*(1325.824 / 1146.96)*(1146.96/ 312.095)
=Net Margin %*Asset Turnover*Equity Multiplier
=0.03 %*1.1559*3.675
=ROA %*Equity Multiplier
=0.04 %*3.675
=0.13 %

Note: The Net Income data used here is two times the semi-annual (Sep. 2025) net income data. The Revenue data used here is two times the semi-annual (Sep. 2025) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Mono Pharmacare's annulized ROA % for the quarter that ended in Sep. 2025 is

ROA %(Q: Sep. 2025 )
=Net Income/Total Assets
=0.41/1146.96
=(Net Income / Revenue)*(Revenue / Total Assets)
=(0.41 / 1325.824)*(1325.824 / 1146.96)
=Net Margin %*Asset Turnover
=0.03 %*1.1559
=0.04 %

Note: The Net Income data used here is two times the semi-annual (Sep. 2025) net income data. The Revenue data used here is two times the semi-annual (Sep. 2025) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Mono Pharmacare Asset Turnover Related Terms


Mono Pharmacare Asset Turnover Historical Data

* Premium members only.

The historical data trend for Mono Pharmacare's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mono Pharmacare Asset Turnover Chart

Mono Pharmacare Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
Asset Turnover
2.52 2.89 1.52 1.70 1.76

Mono Pharmacare Semi-Annual Data
Mar21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
Asset Turnover Get a 7-Day Free Trial Premium Member Only 0.97 0.71 0.97 0.78 0.58

Mono Pharmacare Asset Turnover Competitor Comparison

For the Pharmaceutical Retailers subindustry, Mono Pharmacare's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mono Pharmacare Asset Turnover vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Mono Pharmacare's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Mono Pharmacare's Asset Turnover falls into.


NSE:MONOPHARMA
9GF Score
Mono Pharmacare Ltd NSE:MONOPHARMA
Asset Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mono Pharmacare Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Mono Pharmacare's Asset Turnover for the fiscal year that ended in Mar. 2025 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Mar. 2025 )/( (Total Assets (A: Mar. 2024 )+Total Assets (A: Mar. 2025 ))/ count )
=1683.449/( (811.127+1100.55)/ 2 )
=1683.449/955.8385
=1.76

Mono Pharmacare's Asset Turnover for the quarter that ended in Sep. 2025 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Sep. 2025 )/( (Total Assets (Q: Mar. 2025 )+Total Assets (Q: Sep. 2025 ))/ count )
=662.912/( (1100.55+1193.37)/ 2 )
=662.912/1146.96
=0.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.

Frequently Asked Questions Learn more about Asset Turnover →
What does a Asset Turnover of 0.58 mean?
Mono Pharmacare (NSE:MONOPHARMA) has a Asset Turnover of 0.58 as of Sep. 2025. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Mono Pharmacare and its competitors.
Is Mono Pharmacare's Asset Turnover too high?
Mono Pharmacare's current Asset Turnover is 0.58. Overall, Mono Pharmacare has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Mono Pharmacare's Asset Turnover compare to competitors?
Mono Pharmacare's Asset Turnover of 0.58 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Turnover for a Healthcare Providers & Services company?
A good Asset Turnover depends on the Healthcare Providers & Services industry context. However, Asset Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Turnover mean?
A high Asset Turnover can signal that a stock is expensive relative to its fundamentals. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Mono Pharmacare and its competitors. Mono Pharmacare's current Asset Turnover is 0.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mono Pharmacare stock overvalued right now?
Mono Pharmacare (NSE:MONOPHARMA) has a current Asset Turnover of 0.58. The current Asset Turnover is 0.58. Mono Pharmacare's overall GF Score™ is 9/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Turnover calculated?
Asset Turnover is calculated from a company's financial statements. For Mono Pharmacare (NSE:MONOPHARMA), the current Asset Turnover is 0.58 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mono Pharmacare Business Description

Address 1A, Krinkal Apartment, Opposite Mahalaxmi Temple, Paldi, Ahmedabad, GJ, IND, 380007
Mono Pharmacare Ltd distributes a broad range of pharmaceutical products across India. Its portfolio includes antibiotics, antifungal medicines, cough and cold remedies, antacids, analgesics, nutraceuticals, skincare, antiseptics, cardiac and diabetic drugs, and cosmetic items. The company operates through contract manufacturing, sourcing products from various manufacturers and supplying them to healthcare providers and pharmacies. Revenue is generated through the sales and distribution of these pharmaceutical and healthcare products in the Indian market.
9GF Score

Get the complete analysis for NSE:MONOPHARMA

Asset Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹10.60
Price